Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804530 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Plexxikon.
- Terminated
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT01804530 is a Phase 1 study that was terminated before completion, run by Plexxikon. The registered enrollment target is 59 participants.
The verdict
NCT01804530, a Phase 1 study, was terminated before completion, sponsored by Plexxikon.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
Interventions
- DRUG PLX7486 TsOH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804530
The ClinicalTrials.gov registry entry for NCT01804530 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Plexxikon, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX7486 TsOH is the first listed.
NCT01804530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01804530 about?
NCT01804530 is a clinical study titled "Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors". The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
What is the current status of trial NCT01804530?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2013-08. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT01804530?
The interventions under investigation include: PLX7486 TsOH (DRUG).
Who is sponsoring clinical trial NCT01804530?
This trial is sponsored by Plexxikon, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.